Phase II trial of combination therapy with arsenic trioxide/interferon/zidovudine and conventional chemothrapy for patients with adult T cell leukemia/lymphoma (ATL)
Phase 2
- Conditions
- Adult T cell leukemia/lymphoma
- Registration Number
- JPRN-UMIN000012268
- Lead Sponsor
- Kagoshima University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 9
Inclusion Criteria
Not provided
Exclusion Criteria
1) History of glaucoma 2) Poor control of diabetes mellitus 3) Coronary artery disease/cardiomyopathy/hear failure/arrhythmia 4) HIV antibody, HCV antibody, HBs antigen positive 5) Interstitial pneumonia, pulmonary fibrosis, severe emphysema 6) Acute hepatitis, chronic hepatitis, cirrhosis 7) Malignancy, malignant lymphoma, myelodysplastic syndrome, leukemia 8) Pregnancy 9) Psychological disease 10) History of allergy for arsenic trioxide/interferon/zidovudine
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method